Acorda stock plummets 31% on ‘surprising, puzzling, disconcerting’ FDA drug decision
August 29, 2017 at 08:37 AM EDT
A refusal to file letter means that the company’s drug application wasn’t complete enough and is considered embarrassing for a drug company.